Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Barchart

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Barchart

Read news from The Economist, FT, and more,
with one subscription

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Investors Business Daily

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

Investors Business Daily

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

International Business Times

Novo Nordisk Foundation Expanding Grants Internationally

Novo Nordisk Foundation expands global grant allocation to drive research and innovation beyond Denmark, fostering collaborations and excellence worldwide.

Top News

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Investors Business Daily

FDA Approves Novo Nordisk's Wegovy For Lowering Heart Risks

FDA approves Novo Nordisk's Wegovy for reducing heart risks in weight management. Novo Nordisk's innovative solution targets weight management and heart risks.

Top News

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

FDA approves Wegovy for lowering heart attack and stroke risk in overweight patients

International Business Times

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

Top News

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

FDA approves Wegovy label change to reduce cardiovascular risk in overweight patients, a significant advancement in obesity treatment with potential implic...

Investors Business Daily

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review

The Nasdaq and S&P 500 hit fresh all-time highs, with Nvidia and bitcoin continuing to surge.

Barchart

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Top News

Novo Nordisk CEO Warns Of Health Risks From Semaglutide

Novo Nordisk CEO addresses concerns about compounded semaglutide for diabetes and obesity, emphasizing safety risks and need for FDA-approved medications.

Investors Business Daily

Novo Nordisk Shoots To Record High After New Pill Tops Weight-Loss Blockbuster Wegovy

Novo Nordisk rose to a record high after the drugmaker said its experimental oral weight-loss drug outperformed Wegovy in an early-stage study.

Investors Business Daily

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

Investors Business Daily

Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News

DaVita stock launched Tuesday after Novo Nordisk unveiled the results of its weight-loss drug in kidney disease patients.

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.